WO1991001135A1 - A nutritive composition and a method for its preparation - Google Patents
A nutritive composition and a method for its preparation Download PDFInfo
- Publication number
- WO1991001135A1 WO1991001135A1 PCT/SE1990/000476 SE9000476W WO9101135A1 WO 1991001135 A1 WO1991001135 A1 WO 1991001135A1 SE 9000476 W SE9000476 W SE 9000476W WO 9101135 A1 WO9101135 A1 WO 9101135A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glutamine
- preparation
- sterilized
- packaging device
- remainder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0035—Gamma radiation
Definitions
- the present invention relates to a sterile, aqueous preparation which is intended for administering nutrie ⁇ nts to human beings and animals and containing glutam ⁇ ine, and to a preparation prepared in accordance with the method.
- the invention also relates to a packaging device for handling such a preparation.
- the invention relates to a sterile nutritive composition which contains glutamine together with other nutritive substances, such as a ino acids, fats, and then particularly in emulsion form, energy substrates, such as glucose, sugar alcohols and keto acids, vitamins, mineral substances and/or trace ele ⁇ ments, and to a method of preparing such a sterile nutritive solution.
- a sterile nutritive composition which contains glutamine together with other nutritive substances, such as a ino acids, fats, and then particularly in emulsion form, energy substrates, such as glucose, sugar alcohols and keto acids, vitamins, mineral substances and/or trace ele ⁇ ments, and to a method of preparing such a sterile nutritive solution.
- glutamine has an important significance when used as a component in nutritive solutions. According to some theories, glutamine, which constitutes the most signi ⁇ ficant transporter of nitrogen from muscle, has a stimulating effect on the protein synthesis in muscle tissue. Following serious trauma, surgery, sepsis, etc. , there occurs a drastic reduction in the free glutamine reserve in skeletal muscle (Vinnars E. Bergs- tr ⁇ ra J and Furst P. : Influence of the Postoperative State on the Intracellular Free Amino Acids in Human Muscle Tissue; Annals of Surgery 182:665-671 (1975), and Askanazi J, et al: Muscle and Plasma Amino Acids follow Injury.
- the glutamine is also an essential energy source for the intestinal mucous membrane tissue (Wind ueller H.G. Spaeth A E: Identi ⁇ fication of Ketone Bodies and Glutamine as the Major Respiratory Fuels in Vivo for Postabsorptive Rat Small Intestine, J Biol. Che . 253:69-76 (1978)).
- Wind ueller H.G. Spaeth A E Identi ⁇ fication of Ketone Bodies and Glutamine as the Major Respiratory Fuels in Vivo for Postabsorptive Rat Small Intestine, J Biol. Che . 253:69-76 (1978)
- a certain degree of atrophying or wasting occurs in the mucous membrane of the intestines. Experiments on animals have shown that this negative effect can be counteracted, by administering glutamine intravenously.
- the aforesaid drawbacks and disadvantages are elimi- nated by the present invention, which provides a sterile, aqueous nutritive preparation for administra ⁇ tion to human beings and animals and which contains glutamine in a desired mixture with other desirable nutritive additives.
- the preparation Prior to use, the preparation is completely stable when stored and can be readily con ⁇ verted to an administerable or ready-for-use state, even by relatively unskilled persons. Because there is no marked difference between the preparation when in its administerable state and earlier known nutritive preparations, the inventive preparation can be registered more readily as a drug before the authorities concerned.
- a sterile, aqueous nutritive preparation for administra ⁇ tion to human beings and animals and containing gluta ⁇ mine the preparation being characterized in that the glutamine, in a substantially water-free state, has been sterilized by subjecting the preparation to the influence of ionizing radiation, and subsequently combined with the remainder of the preparation. Because the glutamine, in a dry state, has been sterilized by radiation and the remainder of the preparation exists in the form of a sterile solution or emulsion, the ad- ministerable preparation will also be obtained in a sterile state, provided that measures necessary for maintaining sterility are undertaken when combining the sterilized glutamine with the remainder of the pre ⁇ paration. Such measures are well known to one of normal skill in this art.
- the present invention also relates to a method of preparing a sterile, nutritive preparation intended for administration to human beings and animals and contain- ing glutamine.
- the method is characterized in that the glutamine, in a substantially water-free state, is sterilized separately and alone, by subjecting said glutamine to the influence of ionizing radiation, and in that the sterilized glutamine is then combined with the remainder of the preparation.
- the present invention also relates to a packaging device for providing an administerable, sterile, aqueous nutritive preparation intended for administra- tion to human beings and animals and containing glutamine, said packaging device being characterized in that the device comprises a container constructed from a material which can be penetrated by ionizing radia ⁇ tion and which will not be decomposed by such radia- tion; in that the container contains a desired quantity of substantially water-free glutamine which has been sterilized by the influence of ionizing radiation; and in that the container is intended to be filled, under sterile conditions, with the remainder of the prepara- tion in solution and/or emulsion form, such as to mix with the glutamine and dissolve the same.
- the inventive packaging device consists of a bag-like container made of plastic foil material which contains the sterilized glutamine and which is provided with known means for delivering and withdrawing a liquid preparation.
- FIGS 1-3 of the accompanying drawing illustrate embodiments of a packaging device for providing a nutritive preparation in accordance with the invention.
- Sterile filtration cannot provide a fully acceptable result from the aspect of sterility, particularly when the preparation shall be administered parenterally, where the requirement of complete steri ⁇ lity is strict. Furthermore, sterile filtration is extremely difficult to carry out in practice, when the preparation contains emulsified fat.
- the glutamine and the packaging device in which it is contained are sterilized simultaneously by ionizing radiation, in a manner known per se.
- the radiation concerned may be X- ray radiation, gamma radiation, electron radiation or some other type of ionizing radiation used convention ⁇ ally for sterilizing purposes.
- Gamma radiation emitted from a radioactive nuclide, such as cobalt 60, is often used, as are also high energy electrons from accelera- tors.
- the radiation dosage applied for sterilizing the glutamine and its container is conventional and can be readily established by the skilled person on the basis of simple routine experiments, while taking into con ⁇ sideration such factors as the geometric configuration of the irradiated packaging device, the material from which it is made, temperature and like parameters.
- the radiation dosage applied is normally from 1 to 60 kGy, and then preferably 8-25 kGy.
- the preparation can contain further amino acids, essential and non-essential, carbohydrates, such as different sugar types, for instance glucose, fructose and/or maltose, sugar alcohols, such as sorbitol and xylitol, or keto acids, optionally in the form of salts or esters, water-soluble and/or fat-soluble vitamins, minerals, and/or trace elements.
- An important nutrient is also fat in an emulsified form.
- the components included in the preparation and the quantities in which these components are present is determined by the quantity and composition of the nutrient to be administered.
- the preparation is produced by mixing the ingoing components, in solid, dissolved or emulisified form, with a water phase under sterile conditions, and then incorporating the radiation-sterilized glutamine in the mixture. Because the glutamine is sensitive to heat, incorporation of the glutamine in said mixture should not be effected at too high a temperature, and then preferably not at a temperature above room temperature. It has been found less suitable to first mix all com- ponents in a dry state and then add the water phase, since this requires a higher temperature and/or a longer time period in order to achieve complete dis ⁇ solution.
- the administerable preparation When producing the administerable preparation, it has been found particularly advantageous to either add to the sterilized, substantially water-free glutamine the remaining components of the preparation in a dissolved and/or emulsified form, preferably in a packaging device constructed in accordance with the invention, or alternatively by adding the sterilized, essentially water-free glutamine to the solution or emulsion of the remaining preparation components.
- the administerable preparation containing dissolved glutamine should not be exposed to high temperatures, since the glutamine will then decompose, as explained in the aforegoing. Marked decomposition of the gluta ⁇ mine also occurs when storing the preparation at room temperature. The preparation remains relatively stable, however, under cold conditions, and can be stored in a refrigerator for several months without being impaired to any"serious extent.
- the inventive preparation is particularly suited for parenteral nutritive administration, particularly intravenous administration, to patients who are unable to take-in food in the normal manner, due to injury or illness. High demands are placed on complete sterility of the preparation in cases such as these.
- the prepara ⁇ tion can also be taken orally, either normal ⁇ ly or with the aid of a stomach tube.
- An inventive packaging device for providing an administerable, sterile nutritive preparation contain ⁇ ing glutamine can be constructed in different ways.
- One suitable embodiment of the inventive packaging device comprises a bag-like container made of plastic foil material and containing the sterilized glutamine.
- the packaging device is provided with ports or other known devices through which liquid prepara ⁇ tions can be introduced into and removed from the packaging device under sterile conditions.
- Packaging devices of this kind are known to the art, and it is also known to sterilize empty packaging devices of this kind by ionizing radiation.
- a desired quantity of essentially water-free glutamine is introduced into the packaging device, which is then sealed and sterilized by radiation together with its glutamine content. Subsequent to this sterilizing process, the packaging device and the sterilized glutamine contained therein can be stored for a considerable length of time, before preparing the administerable or ready-for-use preparation.
- the inventive packaging device can also be configured in various ways, for the production of the administer ⁇ able preparation.
- the inventive packaging device comprises only one single space in which the sterilized glutamine is located and to which the remaining components of the preparation are intro ⁇ quizzed, in a dissolved or emulsified state.
- FIG. 1 of the accompanying drawing This Figure illustrates a packaging device 1 having an internal container space 2, in which the dry and sterile gluta ⁇ mine 3 is located.
- the packaging device includes an inlet 4 provided with a closure device 5, through which the remaining components of the preparation are intro ⁇ quizd, and an outlet 6 having a closure device 7, through which the administerable preparation is taken from the packaging device.
- the closure devices 5 and 7 may be configured in different ways. In its simplest and preferred form, in which the packaging device has the form of a plastic-foil bag, the closure devices may simply consist of seam welds formed in the plastic material.
- the inlet When wishing to introduce preparation com ⁇ ponents into the packaging device, the inlet can be simply cut off beneath the seam weld, so as to permit entry to the space 2, or the preparation components can be introduced into the space 2 with the aid of a can- nula, which is inserted through the wall of the pack ⁇ aging device. Removal of administerable preparation can be effected in a similar manner, by cutting open the outlet 6, or with the aid of a cannula inserted through the packaging device wall close to the outlet 6. Intro ⁇ duction and withdrawal with the aid of a cannula has the advantage of ensuring complete sterility of the packaging device content more readily, both before and after preparing the administerable preparation.
- closure devices 5 and 7 may also have the form of known valve devices incorporated in pipes.
- the packaging device may be divided into two spaces, with the glutamine located in one of said spaces.
- This embodiment is illustrated in Figure 2.
- the packaging device 10 is divided into two spaces 11 and 12 which are separated by a partition 13.
- the partition 13 has formed therein a passageway 14, in which a filter 15 may optionally be incorporated.
- This filter for in- stance, may be a sterile filter.
- the glutamine 16 is present in a dry and sterile state in the one space 11, and this space may also be provided with an inlet 17 for the introduction of preparation components.
- the other space is provided with an outlet 18 for the withdrawal of administerable preparation, and option ⁇ ally also with a further inlet 19 through which addi ⁇ tional preparation components can be introduced into the device.
- the two inlets 17 and 19 and the outlet 18 are also provided with suitable closure devices, as described with reference to the earlier embodiment.
- the water phase is introduced through the inlet 17 to the space 11 containing the glutamine 16, optionally to ⁇ gether with dissolved and/or emulsified components, so that the glutamine 16 is dissolved.
- the glutamine solution with the optionally introduced further com- ponents then flows through the passageway 14 and through the filter 15, when present, to the space 12.
- Additional components may optionally be introduced into said space, through the inlet 19, and the administer ⁇ able preparation withdrawn through the outlet 18.
- the first space may include a column-like structure, in which the glutamine is held.
- FIG 3 in which corresponding parts of the packaging device are identified with the same reference signs as those used in Figure 2.
- the first space 11 has a column-like con ⁇ figuration, in which the dry and sterile glutamine 16 is located.
- a passageway or conduit 14 mounted between the first space 11 and the second space 12 is a passageway or conduit 14, in which a filter 15 may be mounted, for instance a sterile filter.
- the glutamine solution is collected in the second space 12 and is admixed optionally with further preparation components, entering through the supply line 19, prior to withdrawing the administerable preparation through the outlet 18.
- the inlet and outlet lines are provided with appropriate closure devices, in a manner similar to the earlier described embodiments.
- the embodiment illustrated in Figure 3 has the advan- tage of enabling dissolution of the glutamine to take place under gentler conditions when the water phase is added.
- All embodiments require the glutamine, enclosed in a dry state in the sealed packaging device, to have been sterilized by ionizing radiation prior to preparing the administerable preparation. Since the dry glutamine has relatively good stability, the glutamine can be stored over a considerable period of time between steriliza- tion and production of the administerable preparation. Complete sterility of the glutamine will be maintained during the whole of this storage period, provided that the packaging device remains fully sealed.
- the inventive packaging device is constructed from a material which will not decompose or emit deleterious reaction products when subjected to the influence of ionizing radiation in the dosages used for sterilization purposes.
- a material which will not decompose or emit deleterious reaction products when subjected to the influence of ionizing radiation in the dosages used for sterilization purposes.
- different known plastic foil materials can be used.
- the foil materials used will also preferably be not-readily permeable to gases.
- Such foil materials may be homogen ⁇ ous or in laminate form, and several types of material which satisfy these requirements are known to the art.
- the packaging device is constructed in detail in a manner which will permit the introduction of the liquid phase, the dissolution of the glutamine and the withdrawal of the administerable preparation to be effected while maintaining sterile conditions. Liquid packaging devices of such designs are also known to the art.
- the present invention provides a sterile, aqueous preparation which contains glutamine and which is intended for administration to human beings and ani ⁇ mals. This has not earlier been possible to achieve.
- the method of preparing the administerable preparation is also simple and the major part of the method is based on known techniques. Empty bag-like packaging devices are already sterilized by ionizing radiation in present times, and it is technically simple to place dry glutamine in the packaging devices prior to ir ⁇ radiation. Conventional methods and also conventional apparatus are found for subsequently introducing the remaining nutritive components, in a dissolved or emulsified state into the packaging devices at desired times.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8902544-9 | 1989-07-17 | ||
| SE8902544A SE8902544L (en) | 1989-07-17 | 1989-07-17 | PREPARATION FOR NUTRITIONAL SUPPLY AND PREPARATION FOR IT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991001135A1 true WO1991001135A1 (en) | 1991-02-07 |
Family
ID=20376555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SE1990/000476 Ceased WO1991001135A1 (en) | 1989-07-17 | 1990-07-03 | A nutritive composition and a method for its preparation |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0434820A1 (en) |
| JP (1) | JPH04500817A (en) |
| SE (1) | SE8902544L (en) |
| WO (1) | WO1991001135A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992009277A1 (en) * | 1990-12-03 | 1992-06-11 | Kabi Pharmacia Ab | Nutrient supply |
| EP0665012A1 (en) * | 1994-01-31 | 1995-08-02 | Snow Brand Milk Products Co., Ltd. | Antiallergy agent and nutritional composition containing glutamine and process for the production thereof |
| EP0666739A4 (en) * | 1992-11-06 | 1996-02-28 | Brigham & Womens Hospital | INTRAVENOUS SOLUTION THAT REDUCES THE LOSS OF PROTEINS IN THE BODY. |
| US7993578B2 (en) | 2004-10-29 | 2011-08-09 | Depuy Spine, Inc. | Methods and kits for aseptic filling of products |
| CN105521481A (en) * | 2014-09-29 | 2016-04-27 | 华仁药业股份有限公司 | Parenteral nutritional composition for injection and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB657295A (en) * | 1942-05-07 | 1951-09-19 | Electronized Chem Corp | Improvements in and relating to methods of sterilizing and preserving foodstuffs, drugs and pharmaceutical preparations |
| EP0116362A2 (en) * | 1983-02-11 | 1984-08-22 | Millipore Corporation | Sterile package for therapeutic composition |
| EP0132632A2 (en) * | 1983-07-21 | 1985-02-13 | Abbott Laboratories | Compartmented flexible solution container |
| WO1987001589A1 (en) * | 1985-09-12 | 1987-03-26 | Brigham And Women's Hospital | Method of treating catabolic dysfunction |
| WO1989003688A1 (en) * | 1987-10-29 | 1989-05-05 | Ab Erik Vinnars | Amino acid composition for parenteral nutritional support and the use thereof |
-
1989
- 1989-07-17 SE SE8902544A patent/SE8902544L/en not_active Application Discontinuation
-
1990
- 1990-07-03 JP JP2510548A patent/JPH04500817A/en active Pending
- 1990-07-03 WO PCT/SE1990/000476 patent/WO1991001135A1/en not_active Ceased
- 1990-07-03 EP EP90911321A patent/EP0434820A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB657295A (en) * | 1942-05-07 | 1951-09-19 | Electronized Chem Corp | Improvements in and relating to methods of sterilizing and preserving foodstuffs, drugs and pharmaceutical preparations |
| EP0116362A2 (en) * | 1983-02-11 | 1984-08-22 | Millipore Corporation | Sterile package for therapeutic composition |
| EP0132632A2 (en) * | 1983-07-21 | 1985-02-13 | Abbott Laboratories | Compartmented flexible solution container |
| WO1987001589A1 (en) * | 1985-09-12 | 1987-03-26 | Brigham And Women's Hospital | Method of treating catabolic dysfunction |
| WO1989003688A1 (en) * | 1987-10-29 | 1989-05-05 | Ab Erik Vinnars | Amino acid composition for parenteral nutritional support and the use thereof |
Non-Patent Citations (1)
| Title |
|---|
| J.E. HOOVER, "Remington's Pharmaceutical Sciences", 15.Ed., 1975, Mack Publishing Co. (Easton, Pennsylvania), see pages 1397-1400 and 1482-1483 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992009277A1 (en) * | 1990-12-03 | 1992-06-11 | Kabi Pharmacia Ab | Nutrient supply |
| EP0666739A4 (en) * | 1992-11-06 | 1996-02-28 | Brigham & Womens Hospital | INTRAVENOUS SOLUTION THAT REDUCES THE LOSS OF PROTEINS IN THE BODY. |
| EP0665012A1 (en) * | 1994-01-31 | 1995-08-02 | Snow Brand Milk Products Co., Ltd. | Antiallergy agent and nutritional composition containing glutamine and process for the production thereof |
| US7993578B2 (en) | 2004-10-29 | 2011-08-09 | Depuy Spine, Inc. | Methods and kits for aseptic filling of products |
| US8187556B2 (en) | 2004-10-29 | 2012-05-29 | Depuy Spine, Inc. | Methods and kits for aseptic filing of products |
| CN105521481A (en) * | 2014-09-29 | 2016-04-27 | 华仁药业股份有限公司 | Parenteral nutritional composition for injection and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| SE8902544D0 (en) | 1989-07-17 |
| EP0434820A1 (en) | 1991-07-03 |
| SE8902544L (en) | 1991-01-18 |
| JPH04500817A (en) | 1992-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010222294B2 (en) | Process and apparatus for producing hydrogen-containing biocompatible solution | |
| EP0059694B1 (en) | Drug administration device | |
| CA1168582A (en) | Dialysis solution containing glucose, amino acids and insulin | |
| EP0522111A1 (en) | System for creating at a site, remote from a sterile environment, a parenteral solution. | |
| WO2014061808A1 (en) | Nutritional composition for gastrostomy-tube patients | |
| EP0172880B2 (en) | Use of long chain and medium chain triglycerides | |
| KR100374436B1 (en) | Peripheral Vein Administration Nutrient Solution | |
| Madan et al. | Total parenteral nutrition | |
| WO1991001135A1 (en) | A nutritive composition and a method for its preparation | |
| EP3427781B1 (en) | Drug and device system for pressurized aerosol therapies into a mammalian hollow space | |
| DE69422637T2 (en) | TRANSDERMAL COMPOSITION OF N- (N- (5- (4- (AMINOIMINOMETHYL) PHENYL-1-OXOPENTYL) -L-ALPHA-ASPARTYL) -L-PHENYLALANINE, OR THEIR ESTER DERIVATIVES, AND THEIR PHARMACEUTICAL SALES | |
| JP4691773B2 (en) | Drug enclosing container set and manufacturing method thereof | |
| US4918193A (en) | Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion | |
| Bramley et al. | Laburnum" poisoning" | |
| JPH0920650A (en) | Total infusion for peripheral intravenous administration | |
| WO2009100591A1 (en) | Use of hydrochloric acid for the manufacture of medicine in treating vascular disease | |
| EP0085045A1 (en) | Methods of preparing and using intravenous nutrient compositions | |
| CN101239018A (en) | Multilayer copolymerized compound membrane soft bagged inosine in sodium chloride injection composition and its manufacturing method | |
| Dudrick et al. | The nutritional care of the cancer patient | |
| JPH0142215B2 (en) | ||
| MACHELLA et al. | Jejunal feeding | |
| JPS5946972A (en) | Medical container | |
| Hovland et al. | A Model System for Direct in vivo Measurement of Absorbed Nutrients in Portal Venous Blood: Applicability to Alcohol Studies | |
| CA1082593A (en) | Low temperature vapor phase sterilization and storage of biologically active injectable materials | |
| CN102525913A (en) | Separated water suspension medicine composed of hydrocortisone butyrate and water containing accessories and used for treating dermatosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1990911321 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1990911321 Country of ref document: EP |
|
| WWR | Wipo information: refused in national office |
Ref document number: 1990911321 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1990911321 Country of ref document: EP |